Vanda Pharmaceuticals Inc VNDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
Trading Information
- Previous Close Price
- $3.59
- Day Range
- $3.61–3.85
- 52-Week Range
- $3.57–9.94
- Bid/Ask
- $3.60 / $3.88
- Shares Outstanding
- 60.47M
- Market Cap
- $230.99M
- Volume/Avg
- 896,877 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 533
- Website
- https://www.vandapharma.com
Valuation
Metric | VNDA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.16 |
Price/Sales | 1.00 |
Price/Cash Flow | — |
Price/Earnings
VNDA
Financial Strength
Metric | VNDA |
|---|---|
Quick Ratio | 1.30 |
Current Ratio | 1.54 |
Interest Coverage | — |
Quick Ratio
VNDA
Profitability
Metric | VNDA |
|---|---|
Return on Assets (Normalized) | −57.78% |
Return on Equity (Normalized) | −89.66% |
Return on Invested Capital (Normalized) | −85.03% |
Return on Assets
VNDA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|l%FlbS | LOCK|N%x> | $139B | |||
| Moderna Inc MRNA | LOCK|#$>@!!> | LOCK|GT | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<!@T<# | LOCK|l>NT$ | $94B | |||
| argenx SE ADR ARGX | LOCK|N?rvHzL | LOCK|K? | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|S?^d%f | LOCK|@#t | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|R$nfK$! | LOCK|%&m@! | $30B | |||
| Incyte Corp INCY | LOCK|<B@#$RT | LOCK|&k | $24B | |||
| BioNTech SE ADR BNTX | LOCK|%Ql>^&# | LOCK|w!D | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|<hjzPc | LOCK|@>&V$ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|<!tkm@< | LOCK|@y% | $15B |
United States